MYPAID 120MG SR TABLETS
Active substance(s): DIHYDROCODEINE TARTRATE
- PDF options:
- View fullscreen
- Download PDF
PDF Transcript
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Mypaid 120mg SR Tablets.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 120mg dihydrocodeine tartrate.
For excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Prolonged-release tablets.
Round, flat, white to off-white tablets, half scored on one side.
4.
CLINICAL PARTICULARS
4.1.
Therapeutic indications
For the relief of severe pain in cancer and other chronic conditions.
4.2.
Posology and method of administration
Oral
The tablets should not be chewed.
Adults and children older than 12 years: 60 mg - 120 mg every 12 hours.
Elderly: Dosage should be reduced.
Children up to 12 years: Not recommended.
4.3.
Contraindications
Hypersensitivity to dihydrocodeine or any of the excipients.
Respiratory depression, obstructive airways disease.
As dihydrocodeine may cause the release of histamine, it should not be given
during an asthma attack.
Avoid in acute alcoholism and where there is a risk of paralytic ileus.
Opioid analgesics should not be administered to patients with increased
intracranial pressure and head injury.
Avoid concomitant use with and for 2 weeks after stopping MAOIs
4.4.
Special warnings and precautions for use
Caution should be exercised in hypotension, hypothyroidism, asthma (see 4.3),
decreased respiratory reserve, prostatic hypertrophy and convulsive disorders.
Severe withdrawal symptoms may occur in dependent patients if treatment is
withdrawn abruptly.
The dose should be reduced in elderly and debilitated patients. Reduce dose
or avoid in hepatic or renal function impairment.
4.5.
Interactions with other medicinal products and other forms of interaction
Opioid analgesics may interact wth the following:
Alcohol - enhanced hypotensive and sedative effects
Antidepressants, Tricyclic - sedative effects possibly increased
Antipsychotics - enhanced hypotensive and sedative effects
Anxiolytics and Hypnotics - increased sedative effect
Cimetidine - metabolism of opioid analgesics inhibited by cimetidine
(increased plasma concentration)
Ciprofloxacin - avoid premedication with opioid analgesics (reduced plasma
concentration of ciprofloxacin) when ciprofloxacin used for surgical
prophylaxis.
Domperidone - opioid analgesics antagonise effects of domperidone on gastrointestinal activity
MAOIs - possible CNS excitation or depression (hypertension or hypotension)
when opioid analgesics given with MAOIs —avoid concomitant use and for 2
weeks after stopping MAOIs
Metoclopramide - opioid analgesics antagonise effects of metoclopramide on
gastro-intestinal activity.
Mexiletine - opioid analgesics delay absorption of mexiletine
Moclobemide - possible CNS excitation or depression (hypertension or
hypotension)
Ritonavir - plasma concentration of opioid analgesics (except methadone)
possibly increased by ritonavir
There is an increased risk of toxicity with myelosuppressive drugs
4.6.
Pregnancy and lactation
Dihydrocodeine has been taken in pregnancy, although there is very little
published about its safety.
Third trimester: Depression of neonatal respiration; withdrawal effects in
neonates of dependent mothers; gastric stasis and risk of inhalation pneumonia
in mother during labour.
Dihydrocodeine has not been reported to be excreted in breast milk. However,
it is advisable that dihydrocodeine only be administered to breast-feeding
mothers if considered essential.
4.7.
Effects on ability to drive and use machines
Dihydrocodeine may cause drowsiness: If affected, patients should not drive
or operate machinery.
4.8.
Undesirable effects
Nausea and vomiting (particularly in initial stages), constipation, and
drowsiness; larger doses may produce respiratory depression and hypotension.
Other side-effects include abdominal pain, difficulty with micturition, urinary
retention, ureteric or biliary spasm, dry mouth, sweating, paraesthesia,
headache, facial flushing, vertigo, bradycardia, tachycardia, palpitations,
postural hypotension, hypothermia, confusion, hallucinations, dysphoria,
mood changes, dependence, miosis, decreased libido or potency, rashes,
urticaria and pruritus.
4.9.
Overdose
Opioid analgesics cause varying degrees of coma, respiratory depression, and
pinpoint pupils. The specific antidote naloxone is indicated if there is coma or
bradypnoea.
Since naloxone has a shorter duration of action than many opioids, close
monitoring and repeated injections are necessary according to the respiratory
rate and depth of coma. Where repeated administration of naloxone is
required, it may be given by continuous intravenous infusion and the rate of
infusion adjusted according to vital signs.
5.
PHARMACOLOGICAL PROPERTIES
5.1.
Pharmacodynamic properties
Pharmacotherapeutic Group: Analgesics, Natural Opium Alkaloids –
Dihydrocodeine
ATC code: NO2A AO8
Dihydrocodeine is a semisynthetic narcotic analgesic with a potency between
morphine and codeine. It acts on opioid receptors in the brain to reduce the
patient's perception of pain and improve the psychological reaction to pain by
reducing the associated anxiety.
5.2.
Pharmacokinetic properties
Dihydrocodeine is well absorbed from the gastrointestinal tract following
administration and plasma levels are maintained throughout the twelve hour
dosing interval.
Like other phenanthrene derivatives, dihydrocodeine is mainly metabolised in
the liver with the resultant metabolites being excreted mainly in the urine.
Metabolism of dihydrocodeine includes o-demethylation, n-demethylation and
6-keto reduction.
5.3.
Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are
additional to that already included in other sections of the SPC.
6.
PHARMACEUTICAL PARTICULARS
6.1.
List of excipients
Glyceryl behenate
Calcium sulphate dihydrate
Copovidone VA 64
Sodium stearyl fumarate
6.2.
Incompatibilities
Not applicable
6.3.
Shelf life
3 years
6.4.
Special precautions for storage
Store below 25oC
6.5.
Nature and contents of container
PVC/PVDC/Aluminium foil blister
Packs containing 56 or 60 tablets. Not all pack sizes may be marketed.
6.6.
Instruction for use and handling
Not applicable
7
MARKETING AUTHORISATION HOLDER
Sandoz Limited
Frimley Business Park,
Frimley,
Camberley,
Surrey,
GU16 7SR,
United Kingdom.
8.
MARKETING AUTHORISATION NUMBER
PL 04416/0582
9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
02/05/2006
10
DATE OF REVISION OF THE TEXT
08/02/2011
1.
NAME OF THE MEDICINAL PRODUCT
Mypaid 120mg SR Tablets.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 120mg dihydrocodeine tartrate.
For excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Prolonged-release tablets.
Round, flat, white to off-white tablets, half scored on one side.
4.
CLINICAL PARTICULARS
4.1.
Therapeutic indications
For the relief of severe pain in cancer and other chronic conditions.
4.2.
Posology and method of administration
Oral
The tablets should not be chewed.
Adults and children older than 12 years: 60 mg - 120 mg every 12 hours.
Elderly: Dosage should be reduced.
Children up to 12 years: Not recommended.
4.3.
Contraindications
Hypersensitivity to dihydrocodeine or any of the excipients.
Respiratory depression, obstructive airways disease.
As dihydrocodeine may cause the release of histamine, it should not be given
during an asthma attack.
Avoid in acute alcoholism and where there is a risk of paralytic ileus.
Opioid analgesics should not be administered to patients with increased
intracranial pressure and head injury.
Avoid concomitant use with and for 2 weeks after stopping MAOIs
4.4.
Special warnings and precautions for use
Caution should be exercised in hypotension, hypothyroidism, asthma (see 4.3),
decreased respiratory reserve, prostatic hypertrophy and convulsive disorders.
Severe withdrawal symptoms may occur in dependent patients if treatment is
withdrawn abruptly.
The dose should be reduced in elderly and debilitated patients. Reduce dose
or avoid in hepatic or renal function impairment.
4.5.
Interactions with other medicinal products and other forms of interaction
Opioid analgesics may interact wth the following:
Alcohol - enhanced hypotensive and sedative effects
Antidepressants, Tricyclic - sedative effects possibly increased
Antipsychotics - enhanced hypotensive and sedative effects
Anxiolytics and Hypnotics - increased sedative effect
Cimetidine - metabolism of opioid analgesics inhibited by cimetidine
(increased plasma concentration)
Ciprofloxacin - avoid premedication with opioid analgesics (reduced plasma
concentration of ciprofloxacin) when ciprofloxacin used for surgical
prophylaxis.
Domperidone - opioid analgesics antagonise effects of domperidone on gastrointestinal activity
MAOIs - possible CNS excitation or depression (hypertension or hypotension)
when opioid analgesics given with MAOIs —avoid concomitant use and for 2
weeks after stopping MAOIs
Metoclopramide - opioid analgesics antagonise effects of metoclopramide on
gastro-intestinal activity.
Mexiletine - opioid analgesics delay absorption of mexiletine
Moclobemide - possible CNS excitation or depression (hypertension or
hypotension)
Ritonavir - plasma concentration of opioid analgesics (except methadone)
possibly increased by ritonavir
There is an increased risk of toxicity with myelosuppressive drugs
4.6.
Pregnancy and lactation
Dihydrocodeine has been taken in pregnancy, although there is very little
published about its safety.
Third trimester: Depression of neonatal respiration; withdrawal effects in
neonates of dependent mothers; gastric stasis and risk of inhalation pneumonia
in mother during labour.
Dihydrocodeine has not been reported to be excreted in breast milk. However,
it is advisable that dihydrocodeine only be administered to breast-feeding
mothers if considered essential.
4.7.
Effects on ability to drive and use machines
Dihydrocodeine may cause drowsiness: If affected, patients should not drive
or operate machinery.
4.8.
Undesirable effects
Nausea and vomiting (particularly in initial stages), constipation, and
drowsiness; larger doses may produce respiratory depression and hypotension.
Other side-effects include abdominal pain, difficulty with micturition, urinary
retention, ureteric or biliary spasm, dry mouth, sweating, paraesthesia,
headache, facial flushing, vertigo, bradycardia, tachycardia, palpitations,
postural hypotension, hypothermia, confusion, hallucinations, dysphoria,
mood changes, dependence, miosis, decreased libido or potency, rashes,
urticaria and pruritus.
4.9.
Overdose
Opioid analgesics cause varying degrees of coma, respiratory depression, and
pinpoint pupils. The specific antidote naloxone is indicated if there is coma or
bradypnoea.
Since naloxone has a shorter duration of action than many opioids, close
monitoring and repeated injections are necessary according to the respiratory
rate and depth of coma. Where repeated administration of naloxone is
required, it may be given by continuous intravenous infusion and the rate of
infusion adjusted according to vital signs.
5.
PHARMACOLOGICAL PROPERTIES
5.1.
Pharmacodynamic properties
Pharmacotherapeutic Group: Analgesics, Natural Opium Alkaloids –
Dihydrocodeine
ATC code: NO2A AO8
Dihydrocodeine is a semisynthetic narcotic analgesic with a potency between
morphine and codeine. It acts on opioid receptors in the brain to reduce the
patient's perception of pain and improve the psychological reaction to pain by
reducing the associated anxiety.
5.2.
Pharmacokinetic properties
Dihydrocodeine is well absorbed from the gastrointestinal tract following
administration and plasma levels are maintained throughout the twelve hour
dosing interval.
Like other phenanthrene derivatives, dihydrocodeine is mainly metabolised in
the liver with the resultant metabolites being excreted mainly in the urine.
Metabolism of dihydrocodeine includes o-demethylation, n-demethylation and
6-keto reduction.
5.3.
Preclinical safety data
There are no pre-clinical data of relevance to the prescriber which are
additional to that already included in other sections of the SPC.
6.
PHARMACEUTICAL PARTICULARS
6.1.
List of excipients
Glyceryl behenate
Calcium sulphate dihydrate
Copovidone VA 64
Sodium stearyl fumarate
6.2.
Incompatibilities
Not applicable
6.3.
Shelf life
3 years
6.4.
Special precautions for storage
Store below 25oC
6.5.
Nature and contents of container
PVC/PVDC/Aluminium foil blister
Packs containing 56 or 60 tablets. Not all pack sizes may be marketed.
6.6.
Instruction for use and handling
Not applicable
7
MARKETING AUTHORISATION HOLDER
Sandoz Limited
Frimley Business Park,
Frimley,
Camberley,
Surrey,
GU16 7SR,
United Kingdom.
8.
MARKETING AUTHORISATION NUMBER
PL 04416/0582
9
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
02/05/2006
10
DATE OF REVISION OF THE TEXT
08/02/2011
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
